Analyzing differences in the costs of treatment across centers within economic evaluations

International Journal of Technology Assessment in Health Care

Volumn 17, Issue 2, 2001, Pages 155-163

  Coyle, Douglas ^a   Drummond, Michael F ^b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Cost effectiveness; External validity; Multicenter clinical trials

Indexed keywords

CANCER RADIOTHERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEAD AND NECK CANCER; HOSPITAL COST; HUMAN; LUNG CARCINOMA; MULTICENTER STUDY; REVIEW;

BRONCHIAL NEOPLASMS; CANADA; CLINICAL TRIALS; HEAD AND NECK NEOPLASMS; HEALTH CARE COSTS; HUMANS; MULTICENTER STUDIES; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 0034968477     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462301105015     Document Type: Review

References (19)

1. Economic analysis in randomised control trials
2. Trials and tribulations: Emerging issues in the design of economic evaluations alongside clinical trials
3. Costs of conventional radical radiotherapy versus continuous hyper-fractionated accelerated radiotherapy (CHART) in the treatment of patients with head and neck cancer and carcinoma of the bronchus
4. The problem of protocol driven costs in pharmacoeconomic analysis
5. Comparing cost-effectiveness across countries: The model of acid-related disease
6. Issues in the cross-national assessment of health technology
7. Economic analysis alongside clinical trials: Revisiting the methodological issues
8. Economic evaluation alongside multinational clinical trials: Study considerations for GUSTO IIb
9. Tests for specification errors in classical least squares regression models
10. Multilevel models and health economics
11. Exorcising protocol-induced spirits: Making the clinical trial relevant for economics
12. Are quality of life, patient preferences, and costs realistic outcomes for clinical trials?
13. Randomised multicentre trials of CHART vs. conventional radiotherapy in head and neck and non-small-cell lung cancer: An interim report
14. The economic evaluation of the FIRST study: Design of a prospective analysis alongside a multinational phase III clinical trial
15. Estimating country specific cost-effectiveness from multinational clinical trials